Excessive vitamin D administration may lead to over-suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease. Use with caution in malabsorption syndromes; efficacy may be limited and/or response may be unpredictable. Use of calcitriol for the treatment of secondary hyperparathyroidism associated with chronic kidney disease is not recommended in rapidly worsening kidney function or in noncompliant patients. Increased serum phosphate levels in renal failure may lead to ectopic calcification; the use of an aluminum-containing phosphate binder is recommended along with a low phosphate diet in these patients. Product may contain coconut oil (capsule). Product may contain palm seed oil (oral solution). Some products may contain tartrazine. Topical use may cause hypercalcemia; if alterations in calcium occur, treatment should be discontinued until levels return to normal. For external use only; not for ophthalmic, oral, or intravaginal use. Should not be applied to facial skin, eyes, or lips. Absorption may be increased with occlusive dressings. Excessive exposure to natural or artificial sunlight, or phototherapy should be avoided or limited. Safety and effectiveness have not been evaluated in erythrodermic, exfoliative, or pustular psoriasis. Serum calcium times phosphorus must not exceed 70 mg^2^/dL^2^.